pretomanid (PA-824) / Global Alliance for TB Drug Development  >>  Phase 2
Welcome,         Profile    Billing    Logout  

12 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pretomanid (PA-824) / Global Alliance for TB Drug Development
NCT00567840: PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis

Completed
2a
69
RoW
PA-824, Rifafour e-275
Global Alliance for TB Drug Development
Pulmonary Tuberculosis
12/07
12/07
NCT00944021: Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (CL-010)

Completed
2
69
NA
PA-824, Rifafour e-275 mg
Global Alliance for TB Drug Development
Pulmonary Tuberculosis
01/10
05/10
NCT01215851: Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001)

Completed
2
85
RoW
PA-824, Pyrazinamide, TMC207, Rifafour, Moxifloxacin
Global Alliance for TB Drug Development
Pulmonary Tuberculosis
05/11
08/11
NCT01498419: Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002)

Completed
2
207
RoW
Moxifloxacin (M), Pretomid (Pa), PA-824, Pyrazinamide (Z), Rifafour
Global Alliance for TB Drug Development
Pulmonary Tuberculosis
04/13
07/13
NCT01691534: Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z)

Completed
2
105
RoW
TMC207 (J), PA-824 (PA), pyrazinamide (Z), clofazimine (C), Rifafour
Global Alliance for TB Drug Development
Pulmonary Tuberculosis
04/13
05/13
NCT02193776: A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis.

Completed
2
240
RoW
PA-824, bedaquiline, TMC207, Sirturo, moxifloxacin, BAY 12-8039, Avelox, Avalon, Avelon, pyrazinamide, isoniazid, rifampicin, pyrazinamide and ethambutol combination tablet
Global Alliance for TB Drug Development
Tuberculosis
02/16
02/18
NCT02256696: Assessing PA-824 for Tuberculosis (the APT Trial)

Completed
2
157
RoW
PA-824, Pretomanid, Rifampin, Rifabutin, Pyrazinamide, Ethambutol, Isoniazid
Johns Hopkins University, University of Cape Town
Pulmonary Tuberculosis
05/22
05/22
PaSEM, NCT04179500: A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis Volunteers

Completed
2
26
RoW
Pretomanid, Pa-824, Bedaquiline, moxifloxacin, pyrazinamide
Global Alliance for TB Drug Development
Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant, Tuberculosis, MDR, Tuberculosis, Drug-Resistant Tuberculosis
06/23
07/24
RAD-TB, NCT06192160: Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis

Not yet recruiting
2
315
RoW
Isoniazid, INH, Rifampicin, RIF, Pyrazinamide, PZA, Ethambutol, EMB, Bedaquiline, BDQ, Pretomanid, Pa, Linezolid, LZD, TBI-223, Sutezolid, SZD
National Institute of Allergy and Infectious Diseases (NIAID), TB Alliance
Pulmonary Tuberculosis
06/25
04/26
NCT06058299: Phase 2 Trial Assessing TBAJ876 or Bedaquiline, with Pretomanid and Linezolid in Adults with Drug-sensitive Pulmonary Tuberculosis

Active, not recruiting
2
309
RoW
TBAJ-876, Pretomanid, PA-824, Dovprela, Linezolid, Zyvox, Bedaquiline, Sirturo, TMC207, HRZE, HR
Global Alliance for TB Drug Development
Pulmonary TB, Pulmonary Tuberculosis, Drug Sensitive Tuberculosis
01/25
06/26
PARADIGM4TB, NCT06114628: Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB

Recruiting
2
2500
RoW
GSK3036656, BTZ-043, Bedaquiline (B), Delamanid (D), Pretomanid (Pa), Moxifloxacin (M), Linezolid (L), Pyrazinamide (Z), Rifampicin (R), Isoniazid (H), Ethambutol (E)
University College, London, Radboud University Medical Center, London School of Hygiene and Tropical Medicine, University of Oxford, Research Center Borstel, Lygature, TASK Applied Science, Vita-Salute San Raffaele University, Helmholtz Zentrum Munchen, KNCV Tuberculosis Foundation, Critical Path Institute, European Lung Foundation, Instituto de Saude Publica da Universidade do Porto, University of Liverpool, Institut de Recherche Pour le Developpment, University of Hamburg-Eppendorf, University of California, San Francisco, TB Alliance, Find, University of Milano, University of St Andrews, Uppsala University, European Respiratory Society, Tuberculosis Network European Trialsgroup, Janssen, LP, Otsuka Pharmaceutical Development & Commercialization, Inc., German Center for Infection Research, LMU University Hospital Munich, University of Cambridge, GlaxoSmithKline
Pulmonary Tuberculosis
02/27
08/27
NCT05971602: Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis

Active, not recruiting
2
514
RoW
Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS), Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS), Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE), Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (XBOS), Isoniazid and Rifampicin (HR)
Bill & Melinda Gates Medical Research Institute, Global Alliance for TB Drug Development, Janssen Pharmaceutica, Otsuka Pharmaceutical Co., Ltd.
Pulmonary Tuberculosis
01/25
01/25

Download Options